Emerging JAK Inhibitors for Patients With Myelofibrosis

Opinion
Video

Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.

Case: A 63-Year-Old Man with Myelofibrosis

Clinical Presentation:

  • A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
  • PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)

Follow up and Clinical Workup at 3 Months:

  • Exam: night sweats improved.
  • Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
  • Some spleen reduction.
  • Patient receives ~1 unit RBC per month.

Follow up and Clinical Workup at 6 Months:

  • Patient reports complaints of fatigue and abdominal pain.
  • Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
  • Patient now receives 2 units RBC per month.
  • Experienced recurrence of SCC.
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content